This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PSC | |
|---|---|
| Name | PSC |
| Specialty | Hepatology, Gastroenterology, Immunology |
PSC Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by progressive inflammation and fibrosis of bile ducts, often associated with inflammatory bowel disease and immune-mediated comorbidity. It leads to biliary strictures, cholestasis, and eventual cirrhosis with complications including cholangiocarcinoma and portal hypertension. Clinical management spans surveillance, endoscopic intervention, liver transplantation, and investigational immunomodulatory and antifibrotic therapies.
The condition commonly abbreviated as PSC denotes a progressive fibroinflammatory cholangiopathy affecting intrahepatic and extrahepatic bile ducts, producing multifocal strictures and beading on cholangiography. Historical descriptions arose in the context of hepatobiliary pathology literature and are documented alongside descriptions of cholangitis syndromes and biliary tract neoplasia. Consensus definitions appear in guidelines produced by specialty societies that focus on hepatology, gastroenterology, and transplant medicine.
Medical: The disorder presents as large-duct disease involving the major extrahepatic bile ducts or small-duct disease confined to intrahepatic biliary radicles, with distinct cholangiographic and histologic features; it is encountered in clinical settings spanning hepatology clinics, transplant centers, and endoscopy suites. Political: The abbreviation appears in nomenclature for public service commissions, political steering committees, and parliamentary oversight bodies in diverse jurisdictions. Technological: PSC is used as an acronym in engineering and information-technology contexts for power supply controllers, phase-shift controllers, and protocol statecharts in embedded systems. Biological: In cell biology, PSC denotes pluripotent stem cells central to regenerative-medicine research, differentiation studies, and developmental biology models.
Etiology remains incompletely defined; prevailing models invoke genetic predisposition interacting with dysregulated immune responses and aberrant gut–liver axis signaling. Associations include susceptibility loci identified in major histocompatibility complex regions and non-HLA genes implicated by genome-wide association studies. Pathophysiology features chronic periductal inflammation, concentric "onion-skin" periductal fibrosis, and progressive obliteration of bile ducts, resulting in cholestasis, biliary epithelial injury, and secondary biliary cirrhosis. Gut-derived factors, microbial dysbiosis, and aberrant lymphocyte homing between intestinal mucosa and biliary epithelium are hypothesized mechanisms linking coexisting inflammatory bowel disease phenotypes to biliary injury.
Diagnosis integrates biochemical cholestatic liver-test abnormalities, cholangiographic imaging demonstrating multifocal strictures and segmental dilatations, and, when needed, histologic confirmation from liver biopsy. Cross-sectional and contrast modalities used include magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography performed by interventional teams, while noninvasive elastography and serum biomarkers aid fibrosis assessment. Surveillance frameworks prioritize periodic imaging and tumor-marker monitoring for early detection of cholangiocarcinoma, with endoscopic evaluation indicated for symptomatic dominant strictures and recurrent cholangitis episodes.
Therapy is stratified into medical, endoscopic, and surgical approaches. Ursodeoxycholic acid has been widely used to modulate cholestasis though randomized trials yield mixed outcome data; symptom-directed agents address pruritus and fat-soluble vitamin deficiency. Endoscopic retrograde interventions manage dominant biliary strictures via balloon dilation or stent placement performed by endoscopy services. Antibiotic regimens and biliary drainage are employed for ascending cholangitis. Definitive therapy for decompensated disease or unresectable biliary malignancy is liver transplantation, coordinated through transplant networks; recurrence post-transplant is a recognized issue. Investigational approaches in clinical trials include bile-acid modulators, antifibrotic agents, biologic immunotherapies, and microbiome-targeted interventions.
Incidence and prevalence vary by region, with higher reported rates in Northern European populations and substantial association with inflammatory bowel disease, particularly ulcerative colitis cohorts managed in gastroenterology centers. Typical onset spans young adulthood to middle age with male predominance in many series. Established risk factors include coexistent colitis phenotypes, specific human leukocyte antigen alleles, and family history; environmental contributors such as prior bacterial exposures and smoking have been variably reported across epidemiologic studies.
Natural history commonly leads to progressive fibrosis, portal hypertension, and liver failure over years to decades, with increased lifetime risk of cholangiocarcinoma and colorectal neoplasia in affected patients. Prognostic models incorporate clinical, biochemical, and imaging variables to stratify transplant timing and surveillance intensity. Active research priorities include elucidation of genetic architecture from population-based cohorts, defining microbiome–immune interactions via multicenter consortia, development of targeted antifibrotic and immunomodulatory agents in randomized trials, and refinement of biomarkers for early detection of biliary malignancy to improve long-term outcomes.